ClinicalTrials.Veeva

Menu

Canadian Study of Trandolapril on Blood Pressure in Hypertensive Patients (TRAIL)

Abbott logo

Abbott

Status and phase

Completed
Phase 4

Conditions

Hypertension

Treatments

Drug: Trandolapril

Study type

Interventional

Funder types

Industry

Identifiers

NCT00233532
CANA-03-003

Details and patient eligibility

About

The TRAIL study was conducted to examine the effects of escalating doses of an ACE inhibitor, trandolapril, on lowering blood pressure in Stage 1-2 hypertensive patients.

Enrollment

2,000 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Stage 1 or 2 Hypertension

Exclusion criteria

  • Uncontrolled diabetes
  • Subject has a hypersensitivity to ACE inhibitor

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

2,000 participants in 3 patient groups

1
Other group
Treatment:
Drug: Trandolapril
2
Other group
Treatment:
Drug: Trandolapril
3
Other group
Treatment:
Drug: Trandolapril

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems